ONCOLIX, INC.
ONCOLIX, INC. (AEPP): 1 pipeline candidate · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.1 months
D/E -1.04 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for ONCOLIX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$123K
Quarterly Burn
$455K
Runway
1.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| prolanta | Phase 1 |
Frequently asked questions
How many drug candidates are in ONCOLIX, INC.'s pipeline?
ONCOLIX, INC. (AEPP) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is ONCOLIX, INC.'s lead drug candidate?
ONCOLIX, INC.'s most advanced tracked candidate is prolanta (Phase 1) for ovarian cancer.
What is ONCOLIX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ONCOLIX, INC. has approximately 1.1 months of cash runway.
Get the full picture on ONCOLIX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.